Functional relevance of genetic variations of endothelial nitric oxide synthase and vascular endothelial growth factor in diabetic coronary microvessel dysfunction

Clinical and Experimental Pharmacology and Physiology

Volumn 40, Issue 4, 2013, Pages 253-261

  Joshi, Mandar S ^a   Berger, Philip J ^b   Kaye, David M ^a   Pearson, James T ^b   Bauer, John A ^c   Ritchie, Rebecca H ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Diabetic complications; Endothelium; Genetic polymorphisms; Microvascular complications; Nitric oxide synthase; Vascular endothelial growth factor

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; NOS3 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; CARDIOVASCULAR RISK; CELL SURVIVAL; CORONARY ARTERY DISEASE; CORONARY MICROVESSEL DYSFUNCTION; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIABETOGENESIS; DISEASE ASSOCIATION; DISEASE COURSE; DNA FLANKING REGION; EARLY DIAGNOSIS; ENDOTHELIAL DYSFUNCTION; ENZYME REGULATION; GENE CONTROL; GENE FUNCTION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTRACELLULAR SIGNALING; INTRON; MICROVASCULATURE; MITOGENESIS; NONHUMAN; PREVALENCE; PROGNOSIS; PROMOTER REGION; PUBERTY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULAR ENDOTHELIUM; ADOLESCENT; ADULT; CHILD; COMPLICATION; CORONARY BLOOD VESSEL; DIABETIC ANGIOPATHY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; PATHOPHYSIOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CORONARY VESSELS; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICROVESSELS; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84875682516     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12070     Document Type: Review

References (112)

1. Linder L, Kiowski W, Buhler FR, Luscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation 1990; 81: 1762-7.
2. Annuk M, Zilmer M, Lind L, Linde T, Fellstrom B. Oxidative stress and endothelial function in chronic renal failure. J. Am. Soc. Nephrol. 2001; 12: 2747-52.
3. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. 1996; 27: 567-74.
4. Morgan DR, Dixon LJ, Hanratty CG et al. Impaired endothelium-dependent and -independent vasodilation in elderly patients with chronic heart failure. Eur. J. Heart Fail. 2004; 6: 901-8.
5. Creager MA, Cooke JP, Mendelsohn ME et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J. Clin. Invest. 1990; 86: 228-34.
6. Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc. Health Risk Manag. 2007; 3: 853-76.
7. Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5.
8. Dejkhamron P, Menon RK, Sperling MA. Childhood diabetes mellitus: Recent advances and future prospects. Indian J. Med. Res. 2007; 125: 231-50.
9. Lasker RD. The diabetes control and complications trial. Implications for policy and practice. N. Engl. J. Med. 1993; 329: 1035-6.
10. Deckert T, Poulsen JE, Larsen M. Importance of outpatient supervision in the prognosis of juvenile diabetes mellitus: A cost/benefit analysis. Diabetes Care 1978; 1: 281-4.
11. McGill HC Jr, McMahan CA, Herderick EE, Malcom GT, Tracy RE, Strong JP. Origin of atherosclerosis in childhood and adolescence. Am. J. Clin. Nutr. 2000; 72 (Suppl.): S1307-15.
12. Drexler H, Hornig B. Endothelial dysfunction in human disease. J. Mol. Cell. Cardiol. 1999; 31: 51-60.
13. Gibney J, Turner B, Weis U et al. Reduced forearm reactive hyperaemia in normoalbuminuric subjects with Type 1 diabetes and retinopathy. Diabet. Med. 2004; 21: 931-5.
14. Wiltshire EJ, Gent R, Hirte C, Pena A, Thomas DW, Couper JJ. Endothelial dysfunction relates to folate status in children and adolescents with type 1 diabetes. Diabetes 2002; 51: 2282-6.
15. Dyck PJ, Davies JL, Clark VM et al. Modeling chronic glycemic exposure variables as correlates and predictors of microvascular complications of diabetes. Diabetes Care 2006; 29: 2282-8.
16. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ. Res. 2000; 87: 840-4.
17. Stehouwer CD, Lambert J, Donker AJ, van Hinsbergh VW. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc. Res. 1997; 34: 55-68.
18. Berenson GS, Srinivasan SR, Nicklas TA. Atherosclerosis: A nutritional disease of childhood. Am. J. Cardiol. 1998; 82 (Suppl.): T22-9.
19. Furumoto T, Saito N, Dong J, Mikami T, Fujii S, Kitabatake A. Association of cardiovascular risk factors and endothelial dysfunction in Japanese hypertensive patients: Implications for early atherosclerosis. Hypertens. Res. 2002; 25: 475-80.
20. Landmesser U, Hornig B, Drexler H. Endothelial function: A critical determinant in atherosclerosis? Circulation 2004; 109 (Suppl.): II27-33.
21. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: The role of endothelial dysfunction. Clin. Sci. 2005; 109: 143-59.
22. Marcovecchio ML, Giannini C, Widmer B et al. C-Reactive protein in relation to the development of microalbuminuria in type 1 diabetes: The Oxford Regional Prospective Study. Diabetes Care 2008; 31: 974-6.
23. Joshi MS, Tong L, Cook AC et al. Increased myocardial prevalence of C-reactive protein in human coronary heart disease: Direct effects on microvessel density and endothelial cell survival. Cardiovasc. Pathol. 2012; 21: 428-35.
24. Han B, Baliga R, Huang H, Giannone PJ, Bauer JA. Decreased cardiac expression of vascular endothelial growth factor and redox imbalance in murine diabetic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 2009; 297: H829-35.
25. Venardos K, Zhang WZ, Lang C, Kaye DM. Effect of peroxynitrite on endothelial l-arginine transport and metabolism. Int. J. Biochem. Cell Biol. 2009; 41: 2522-7.
26. Venardos KM, Zatta AJ, Marshall T, Ritchie R, Kaye DM. Reduced l-arginine transport contributes to the pathogenesis of myocardial ischemia-reperfusion injury. J. Cell. Biochem. 2009; 108: 156-68.
27. Venardos K, Enriquez C, Marshall T, Chin-Dusting JP, Ahlers B, Kaye DM. Protein kinase C mediated inhibition of endothelial l-arginine transport is mediated by MARCKS protein. J. Mol. Cell. Cardiol. 2009; 46: 86-92.
28. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J. Clin. Invest. 2001; 108: 1341-8.
29. Zhang J, Zhang X, Li H et al. Hyperglycaemia exerts deleterious effects on late endothelial progenitor cell secretion actions. Diab. Vasc. Dis. Res. 2013; 10: 49-56.
30. Kawashima S, Yokoyama M. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2004; 24: 998-1005.
31. Marcovecchio ML, Chiarelli F. Microvascular disease in children and adolescents with type 1 diabetes and obesity. Pediatr. Nephrol. 2011; 26: 365-75.
32. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: Evidence, mechanisms, and therapeutic implications. Endocr. Rev. 2004; 25: 543-67.
33. Cosentino F, Luscher TF. Endothelial dysfunction in diabetes mellitus. J. Cardiovasc. Pharmacol. 1998; 32 (Suppl. 3): S54-61.
34. Scognamiglio R, Avogaro A, Casara D et al. Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. 1998; 31: 404-12.
35. Hayat SA, Patel B, Khattar RS, Malik RA. Diabetic cardiomyopathy: Mechanisms, diagnosis and treatment. Clin. Sci. 2004; 107: 539-57.
36. Knoebel SB, McHenry PL, Phillips JF, Pauletto FJ. Coronary collateral circulation and myocardial blood flow reserve. Circulation 1972; 46: 84-94.
37. Kountz WB, Smith JR. The flow of blood in the coronary arteries in pathological hearts. J. Clin. Invest. 1938; 17: 147-52.
38. Bourdarias JP. Coronary reserve: Concept and physiological variations. Eur. Heart J. 1995; 16 (Suppl. I): 2-6.
39. Camici PG, Crea F. Coronary microvascular dysfunction. N. Engl. J. Med. 2007; 356: 830-40.
40. Duncker DJ, Bache RJ. Regulation of coronary blood flow during exercise. Physiol. Rev. 2008; 88: 1009-86.
41. Strauer BE, Motz W, Vogt M, Schwartzkopff B. Evidence for reduced coronary flow reserve in patients with insulin-dependent diabetes. A possible cause for diabetic heart disease in man. Exp. Clin. Endocrinol. Diabetes 1997; 105: 15-20.
42. Strauer BE, Motz W, Vogt M, Schwartzkopff B. Impaired coronary flow reserve in NIDDM. A possible role for diabetic cardiopathy in humans. Diabetes 1997; 46 (Suppl. 2): S119-24.
43. Nahser PJ Jr, Brown RE, Oskarsson H, Winniford MD, Rossen JD. Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation 1995; 91: 635-40.
44. Sabri A, Samuel JL, Marotte F, Poitevin P, Rappaport L, Levy BI. Microvasculature in angiotensin II-dependent cardiac hypertrophy in the rat. Hypertension 1998; 32: 371-5.
45. Greene AS, Tonellato PJ, Lui J, Lombard JH, Cowley AW Jr. Microvascular rarefaction and tissue vascular resistance in hypertension. Am. J. Physiol. 1989; 256: H126-31.
46. Kubis N, Richer C, Domergue V, Giudicelli JF, Levy BI. Role of microvascular rarefaction in the increased arterial pressure in mice lacking for the endothelial nitric oxide synthase gene (eNOS3-/-). J. Hypertens. 2002; 20: 1581-7.
47. Agabiti-Rosei E. Structural and functional changes of the microcirculation in hypertension: Influence of pharmacological therapy. Drugs 2003; 63: 19-29.
48. Levy BI, Duriez M, Samuel JL. Coronary microvasculature alteration in hypertensive rats. Effect of treatment with a diuretic and an ACE inhibitor. Am. J. Hypertens. 2001; 14: 7-13.
49. Jenkins MJ, Edgley AJ, Sonobe T et al. Dynamic synchrotron imaging of diabetic rat coronary microcirculation in vivo. Arterioscler. Thromb. Vasc. Biol. 2012; 32: 370-7.
50. Embrey RP, Brooks LA, Dellsperger KC. Mechanism of coronary microvascular responses to metabolic stimulation. Cardiovasc. Res. 1997; 35: 148-57.
51. Shoukry A, Shalaby SM, Abdelazim S et al. Endothelial nitric oxide synthase gene polymorphisms and the risk of diabetic nephropathy in type 2 diabetes mellitus. Genet. Test Mol. Biomarkers 2012; 16: 574-9.
52. Suganthalakshmi B, Anand R, Kim R et al. Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Mol. Vis. 2006; 12: 336-41.
53. Zhang C, Lopez-Ridaura R, Hunter DJ, Rifai N, Hu FB. Common variants of the endothelial nitric oxide synthase gene and the risk of coronary heart disease among U.S. diabetic men. Diabetes 2006; 55: 2140-7.
54. Chen Y, Dawes PT, Mattey DL. Polymorphism in the vascular endothelial growth factor A (VEGFA) gene is associated with serum VEGF-A level and disease activity in rheumatoid arthritis: Differential effect of cigarette smoking. Cytokine 2012; 58: 390-7.
55. Petrovic D, Verhovec R, Globocnik Petrovic M, Osredkar J, Peterlin B. Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes. Cardiology 2007; 107: 291-5.
56. Joshi MS, Mineo C, Shaul PW, Bauer JA. Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: Altered caveolar localization and impaired response to shear. FASEB J. 2007; 21: 2655-63.
57. Joshi MS, Wattanapitayakul S, Schanbacher BL, Bauer JA. Effects of human endothelial gene polymorphisms on cellular responses to hyperglycaemia. Role of NOS3 (Glu298Asp) and ACE (I/D) polymorphisms. Diab. Vasc. Dis. Res. 2011; 8: 276-83.
58. Strowig S, Raskin P. Glycemic control and diabetic complications. Diabetes Care 1992; 15: 1126-40.
59. The Diabetes Control and Complications Trial Research Group. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. Diabetes 1997; 46: 1829-39.
60. Servos S, Zachary I, Martin JF. VEGF modulates NO production: The basis of a cytoprotective effect? Cardiovasc. Res. 1999; 41: 509-10.
61. Bouloumie A, Schini-Kerth VB, Busse R. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc. Res. 1999; 41: 773-80.
62. Murohara T, Asahara T, Silver M et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J. Clin. Invest. 1998; 101: 2567-78.
63. Moncada S, Higgs A. The l-arginine-nitric oxide pathway. N. Engl. J. Med. 1993; 329: 2002-12.
64. Cines DB, Pollak ES, Buck CA et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-61.
65. Aicher A, Heeschen C, Mildner-Rihm C et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med. 2003; 9: 1370-6.
66. Furchgott RF, Carvalho MH, Khan MT, Matsunaga K. Evidence for endothelium-dependent vasodilation of resistance vessels by acetylcholine. Blood Vessels 1987; 24: 145-9.
67. Furchgott RF, Jothianandan D, Cherry PD. Endothelium-dependent responses: The last three years. Bibl. Cardiol. 1984; 38: 1-15.
68. van Hinsbergh VW. The endothelium. Vascular control of haemostasis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2001; 95: 198-201.
69. Wang XL, Wang J. Smoking-gene interaction and disease development. Relevance to pancreatic cancer and atherosclerosis. World J. Surg. 2005; 29: 344-53.
70. Guzik TJ, Korbut R, Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. J. Physiol. Pharmacol. 2003; 54: 469-87.
71. Mihm MJ, Yu F, Reiser PJ, Bauer JA. Effects of peroxynitrite on isolated cardiac trabeculae: Selective impact on myofibrillar energetic controllers. Biochimie 2003; 85: 587-96.
72. Mihm MJ, Jing L, Bauer JA. Nitrotyrosine causes selective vascular endothelial dysfunction and DNA damage. J. Cardiovasc. Pharmacol. 2000; 36: 182-7.
73. Mihm MJ, Coyle CM, Schanbacher BL, Weinstein DM, Bauer JA. Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure. Cardiovasc. Res. 2001; 49: 798-807.
74. Gharavi NM, Baker NA, Mouillesseaux KP et al. Role of endothelial nitric oxide synthase in the regulation of SREBP activation by oxidized phospholipids. Circ. Res. 2006; 98: 768-76.
75. Govers R, Rabelink TJ. Cellular regulation of endothelial nitric oxide synthase. Am. J. Physiol. Renal Physiol. 2001; 280: F193-206.
76. Fisher AB, Al-Mehdi AB, Manevich Y. Shear stress and endothelial cell activation. Crit. Care Med. 2002; 30 (Suppl.): S192-7.
77. Fisslthaler B, Dimmeler S, Hermann C, Busse R, Fleming I. Phosphorylation and activation of the endothelial nitric oxide synthase by fluid shear stress. Acta Physiol. Scand. 2000; 168: 81-8.
78. Fleming I, Bauersachs J, Busse R. Calcium-dependent and calcium-independent activation of the endothelial NO synthase. J. Vasc. Res. 1997; 34: 165-74.
79. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am. J. Physiol. Regul. Intergr. Comp. Physiol. 2003; 284: R1-12.
80. Wattanapitayakul SK, Mihm MJ, Young AP, Bauer JA. Therapeutic implications of human endothelial nitric oxide synthase gene polymorphism. Trends Pharmacol. Sci. 2001; 22: 361-8.
81. Fairchild TA, Fulton D, Fontana JT, Gratton JP, McCabe TJ, Sessa WC. Acidic hydrolysis as a mechanism for the cleavage of the Glu (298)>Asp variant of human endothelial nitric-oxide synthase. J. Biol. Chem. 2001; 276: 26674-9.
82. Casas JP, Bautista LE, Humphries SE, Hingorani AD. Endothelial nitric oxide synthase genotype and ischemic heart disease. Meta-analysis of 26 studies involving 23028 subjects. Circulation 2004; 109: 1359-65.
83. Miyamoto Y, Saito Y, Kajiyama N et al. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 1998; 32: 3-8.
84. Stangl K, Cascorbi I, Laule M et al. High CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery disease. Pharmacogenetics 2000; 10: 133-40.
85. Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat. Med. 1996; 2: 41-5.
86. Taverna MJ, Sola A, Guyot-Argenton C et al. eNOS4 polymorphism of the endothelial nitric oxide synthase predicts risk for severe diabetic retinopathy. Diabet. Med. 2002; 19: 240-5.
87. Durham JT, Herman IM. Microvascular modifications in diabetic retinopathy. Curr. Diab. Rep. 2011; 11: 253-64.
88. Nakayama M, Yasue H, Yoshimura M et al. T-786>C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999; 99: 2864-70.
89. Joshi MS, Bauer JA. Preliminary computational modeling of nitric oxide synthase 3 interactions with caveolin-1: Influence of exon 7 Glu298Asp polymorphism. Acta Biochim. Biophys. Sin. 2008; 40: 47-54.
90. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 2005; 94: 209-31.
91. Michell BJ, Griffiths JE, Mitchelhill KI et al. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr. Biol. 1999; 9: 845-8.
92. Hajduch E, Litherland GJ, Hundal HS. Protein kinase B (PKB/Akt): A key regulator of glucose transport? FEBS Lett. 2001; 492: 199-203.
93. Murohara T, Asahara T. Nitric oxide and angiogenesis in cardiovascular disease. Antioxid. Redox Signal. 2002; 4: 825-31.
94. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem. Sci. 2003; 28: 488-94.
95. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003; 9: 669-76.
96. Aramoto H, Breslin JW, Pappas PJ, Hobson RW 2nd, Duran WN. Vascular endothelial growth factor stimulates differential signaling pathways in in vivo microcirculation. Am. J. Physiol. Heart Circ. Physiol. 2004; 287: H1590-8.
97. Kliche S, Waltenberger J. VEGF receptor signaling and endothelial function. IUBMB Life 2001; 52: 61-6.
98. Kroll J, Waltenberger J. A novel function of VEGF receptor-2 (KDR): Rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells. Biochem. Biophys. Res. Commun. 1999; 265: 636-9.
99. Affara NI, Robertson FM. Vascular endothelial growth factor as a survival factor in tumor-associated angiogenesis. In Vivo 2004; 18: 525-42.
100. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999; 13: 9-22.
101. Tober KL, Cannon RE, Spalding JW et al. Comparative expression of novel vascular endothelial growth factor/vascular permeability factor transcripts in skin, papillomas, and carcinomas of v-Ha-ras Tg AC transgenic mice and FVB/N mice. Biochem. Biophys. Res. Commun. 1998; 247: 644-53.
102. Saito M, Usuku K, Nobuhara Y et al. Serum concentration and genetic polymorphism in the 5′-untraslated region of VEGF is not associated with susceptibility to HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) in HTLV-I infected individuals. J. Neurol. Sci. 2004; 219: 157-61.
103. Papazoglou D, Galazios G, Papatheodorou K et al. Vascular endothelial growth factor gene polymorphisms and idiopathic recurrent pregnancy loss. Fertil. Steril. 2005; 83: 959-63.
104. Storkebaum E, Carmeliet P. VEGF: A critical player in neurodegeneration. J. Clin. Invest. 2004; 113: 14-8.
105. Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes 2004; 53: 861-4.
106. Yang Y, Andresen BT, Yang K, Zhang Y, Li X, Wang H. Association of vascular endothelial growth factor -634C/G polymorphism and diabetic retinopathy in type 2 diabetic Han Chinese. Exp. Biol. Med. 2010; 235: 1204-11.
107. Awata T, Inoue K, Kurihara S et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002; 51: 1635-9.
108. Shahbazi M, Fryer AA, Pravica V et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J. Am. Soc. Nephrol. 2002; 13: 260-4.
109. Horowitz JR, Rivard A, van der Zee R et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler. Thromb. Vasc. Biol. 1997; 17: 2793-800.
110. Lopez JJ, Laham RJ, Carrozza JP et al. Hemodynamic effects of intracoronary VEGF delivery: Evidence of tachyphylaxis and NO dependence of response. Am. J. Physiol. 1997; 273: H1317-23.
111. Huynh K, McMullen JR, Julius TL et al. Cardiac-specific IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy. Diabetes 2010; 59: 1512-20.
112. Ritchie RH, Love JE, Huynh K et al. Enhanced phosphoinositide 3-kinase (p110alpha) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes. Diabetologia 2012; 55: 3369-81.